❗[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 29, 2023 Please take a moment to read this special message from our sponsor, Autonomix. For many, pain can be a constant in life, which is why painkillers are such a huge market – despite typically being a temporary (and sometimes dangerous) "band-aid" solution. Autonomix has a better idea: Target pain at its source in the nervous system. Alongside pain management, their breakthrough nerve-sensing technology has the potential to help treat a wide range of disorders including high blood pressure and digestive issues. It's all with one tiny microchip that's intended to target nerve signals at an accuracy never seen before. The team has 100+ patents issued and pending, and with an estimated total of $100B+ in markets to address, we believe it's a unique opportunity for investors. [Subscribe to updates and see how you can invest in Autonomix before their planned NASDAQ listing.]( (By clicking this link, you agree to receive future emails from Autonomix about company news and updates. You can opt out at any time. - [Privacy Policy]( Disclosure: This is a paid advertisement for Autonomix's Regulation A+ Offering. Please read the offering circular at [invest.autonomix.com]( Copyright @ 2023 Strikepoint Media Our address is 580 Broadway St #201b, Laguna Beach, CA 92651. To update your preferences or unsubscribe, [click here](. (You can also send your request to Customer Care  at the street address above.) This is a paid message provided to our subscribers. Although we have sent you this email, Trade Stocks does not endorse this product or featured company nor is it responsible for it’s content. The opinions represented in this email advertisement are not those of [TradeStocks.com]( , and we make no guarantee or warranty about what is mentioned above. We respect your privacy and that is why this email has been sent directly from Trade Stocks. Trade Stocks does not provide our email lists to third party companies unless you have directly opted in for communication for that company. This is consistent with our [Privacy Policy](.